v3.26.3
Condensed Statement of Cash Flows - Pathfinder - Interim - USD ($)
 4 Months Ended 5 Months Ended 6 Months Ended
Dec. 31, 2025
Dec. 31, 2025
Jun. 30, 2026
Cash flows from operating activities:      
Net loss $ (152,717,402)   $ (188,134,733)
Changes in assets and liabilities:      
Accounts payable and accrued liabilities 233,468   (1,818,138)
Related party payable 170,625   1,980,386
Net cash used in operating activities (716,710)   (1,329,805)
Cash flows from investing activities:      
Net cash used in investing activities (214,000,000)    
Cash flows from financing activities:      
Payments of deferred offering costs     (971,630)
Net cash provided by financing activities 214,766,705   1,427,550
Net increase in cash and cash equivalents   97,745
Cash, cash equivalents, and restricted cash at beginning of period 0   49,995
Cash, cash equivalents, and restricted cash at end of period 49,995 $ 49,995 147,740
Reconciliation of cash, cash equivalents and restricted cash:      
Cash and cash equivalents 0 0 97,745
Restricted cash 49,995 49,995 49,995
Total cash, cash equivalents, and restricted cash 49,995 49,995 147,740
Non-cash financing activities:      
Unpaid deferred offering costs 3,802,903   1,751,466
Pathfinder      
Cash flows from operating activities:      
Net loss   (907,308) (2,218,198)
Changes in assets and liabilities:      
Accounts payable and accrued liabilities   273,056 (164,574)
Interest payable, related party   6,032 86,997
Related party payable   170,625 157,500
Net cash used in operating activities   (457,595) (2,138,275)
Cash flows from investing activities:      
Payments made on behalf of related party   (716,710) (2,399,180)
Net cash used in investing activities   (716,710) (2,399,180)
Cash flows from financing activities:      
Proceeds from note payable, related party   1,174,305 5,380,483
Payments of deferred offering costs     (53,346)
Net cash provided by financing activities   1,174,305 5,327,137
Net increase in cash and cash equivalents     789,682
Cash, cash equivalents, and restricted cash at beginning of period   0 0
Cash, cash equivalents, and restricted cash at end of period 0 0 789,682
Reconciliation of cash, cash equivalents and restricted cash:      
Cash and cash equivalents 0 0 789,682
Restricted cash 0 0 0
Total cash, cash equivalents, and restricted cash $ 0 0 789,682
Non-cash financing activities:      
Unpaid deferred offering costs   $ 477,531 $ 22,470